>Biogen Idec says a mid-stage trial of a new MS drug met its goal of demonstrating reduced numbers of brain lesions compared to a placebo. Report
> A group of 10 biotech and healthcare companies are preparing to go public in London, drawn by AIM's fast-track listing process. The companies include San Francisco-based Entelos, which has been making computer simulations to study skin allergies. Report
> Vertex Pharmaceuticals' Hepatitis C pill was found effective in a small study. Report
> Serono says that its recombinant human growth hormone for treating HIV-associated Adipose Redistribution Syndrome hit all primary and secondary endpoints outlined in a pivotal Phase III trial. Serono says it will file a supplemental NDA for the growth hormone in the first half of this year. The therapy is intended to treat the accumulation of fat under the abdominal muscle wall. Article
> Bristol-Myers Squibb and Gilead Sciences say they have obtained data supporting the bioequivalence of a new formulation of the fixed-dose combination of BMS's Sustiva and Gilead's Truvada. Release
> Endo Pharmaceuticals has licensed the North American rights to Synera. Report
> Alkermes and Eli Lilly have agreed to jointly develop an inhalable version of an osteoporosis therapy. Report
> The FDA has put a new therapy being developed by Medarex on the fast track. Valortim could be used to combat anthrax. Report
> Phytopharm has inked a global distribution deal with Schering-Plough for Phytopica, a plant-based therapy used to help create healthy skin and coat for dogs. Report
> Analysts report that AstraZeneca is facing a significant risk it may lose its patent on its blockbuster heart drug, Toprol XL. Report
> Chromos Molecular Systems and Pfizer have expanded their collaboration deal. Release
> Protalex has raised $5.8 million through a private placement. Release
> Hana Biosciences says it has recorded positive results for its Phase I trial of Zensana for nausea and vomiting. Release
And Finally… In San Diego, if you want to play with the big boys and girls in biotech, it helps to surf. Article